PharmaEssentia Management
Management criteria checks 3/4
PharmaEssentia's CEO is Ko-Chung Lin, appointed in Jan 2017, has a tenure of 7.83 years. directly owns 1.73% of the company’s shares, worth NT$3.56B. The average tenure of the management team and the board of directors is 5.1 years and 3.3 years respectively.
Key information
Ko-Chung Lin
Chief executive officer
n/a
Total compensation
CEO salary percentage | n/a |
CEO tenure | 7.8yrs |
CEO ownership | 1.7% |
Management average tenure | 5.1yrs |
Board average tenure | 3.3yrs |
Recent management updates
Recent updates
We Think That There Are Issues Underlying PharmaEssentia's (TWSE:6446) Earnings
Aug 20PharmaEssentia Corporation's (TWSE:6446) 37% Price Boost Is Out Of Tune With Revenues
Jul 02PharmaEssentia Corporation's (TWSE:6446) 37% Price Boost Is Out Of Tune With Revenues
Jul 02Is There An Opportunity With PharmaEssentia Corporation's (TWSE:6446) 25% Undervaluation?
Apr 02Downgrade: Here's How Analysts See PharmaEssentia Corporation (GTSM:6446) Performing In The Near Term
Mar 18PharmaEssentia Corporation (GTSM:6446) Just Reported And Analysts Have Been Cutting Their Estimates
Mar 06Things Look Grim For PharmaEssentia Corporation (GTSM:6446) After Today's Downgrade
Mar 04PharmaEssentia (GTSM:6446) Is Using Debt Safely
Feb 10What Type Of Returns Would PharmaEssentia's(GTSM:6446) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?
Jan 06CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Jun 30 2024 | n/a | n/a | NT$1b |
Mar 31 2024 | n/a | n/a | NT$442m |
Dec 31 2023 | n/a | n/a | -NT$624m |
Sep 30 2023 | n/a | n/a | -NT$890m |
Jun 30 2023 | n/a | n/a | -NT$1b |
Mar 31 2023 | n/a | n/a | -NT$2b |
Dec 31 2022 | n/a | n/a | -NT$1b |
Sep 30 2022 | n/a | n/a | -NT$2b |
Jun 30 2022 | n/a | n/a | -NT$2b |
Mar 31 2022 | n/a | n/a | -NT$3b |
Dec 31 2021 | NT$9m | NT$9m | -NT$3b |
Sep 30 2021 | n/a | n/a | -NT$3b |
Jun 30 2021 | n/a | n/a | -NT$3b |
Mar 31 2021 | n/a | n/a | -NT$2b |
Dec 31 2020 | NT$9m | NT$9m | -NT$2b |
Sep 30 2020 | n/a | n/a | -NT$1b |
Jun 30 2020 | n/a | n/a | -NT$862m |
Mar 31 2020 | n/a | n/a | -NT$856m |
Dec 31 2019 | NT$9m | NT$8m | -NT$843m |
Compensation vs Market: Insufficient data to establish whether Ko-Chung's total compensation is reasonable compared to companies of similar size in the TW market.
Compensation vs Earnings: Ko-Chung's compensation has been consistent with company performance over the past year.
CEO
Ko-Chung Lin
7.8yrs
Tenure
NT$9,389,000
Compensation
Mr. Ko-Chung Lin, Ph D., is the Founder and Chief Strategy Officer of PharmaEssentia Corporation and has been its Chief Executive Officer since January 01, 2017. He also serves as a Director at PharmaEssen...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Chairman & Chief Pharmaceutical Officer | 12.2yrs | NT$8.49m | 1.05% NT$ 2.2b | |
Founder | 7.8yrs | NT$9.39m | 1.73% NT$ 3.6b | |
President | no data | NT$8.49m | 0.61% NT$ 1.2b | |
Accounting Manager & Senior Manager of Finance | 9.1yrs | no data | no data | |
VP and Head of Business Operations & Strategy | 2.8yrs | no data | no data | |
Chief Scientific Officer | 2.3yrs | no data | 0.010% NT$ 21.0m | |
VP and Head of Corporate Communications & Advocacy | 2.8yrs | no data | no data | |
Senior VP and Head of Sales & Marketing | 3.8yrs | no data | no data | |
Senior VP & Head of People | 2.8yrs | no data | no data | |
Chief Medical Officer | 7.8yrs | no data | 0.0061% NT$ 12.5m | |
Head of Japan Medical Affairs | 6.3yrs | no data | no data | |
Chief Operating Officer of Taichung Plant | 6.3yrs | no data | no data |
5.1yrs
Average Tenure
Experienced Management: 6446's management team is seasoned and experienced (5.1 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Chairman & Chief Pharmaceutical Officer | 12.2yrs | NT$8.49m | 1.05% NT$ 2.2b | |
Founder | 3.3yrs | NT$9.39m | 1.73% NT$ 3.6b | |
President | 9.5yrs | NT$8.49m | 0.61% NT$ 1.2b | |
Independent Director | less than a year | no data | no data | |
Independent Director | less than a year | no data | 0.13% NT$ 260.5m | |
Independent Director | 10.7yrs | NT$120.00k | 0.029% NT$ 59.1m | |
Independent Director | 6.4yrs | NT$120.00k | 0.00060% NT$ 1.2m | |
Independent Director | less than a year | no data | 0.0012% NT$ 2.5m | |
Chairperson of Japan | 3.5yrs | no data | no data | |
Director | 3.3yrs | NT$95.00k | 0.24% NT$ 502.1m | |
Director | less than a year | no data | no data | |
Director | less than a year | no data | no data |
3.3yrs
Average Tenure
Experienced Board: 6446's board of directors are considered experienced (3.3 years average tenure).